MRK
Stock Details
MRK is Merck & Co., Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 89.80$. Average daily volumn in 3 months 12.48M. Market cap 235.57B
Stock symbol : MRK. Exchange : NYSE. Currency : USD Lastest price : 93.15$. Total volume : 871.25k. Market state REGULAR Click reload if you want to check the lastest price on market!!!
Merck & Co., Inc. (MRK)
Last Price
93.15$Change
0.03Volume
871.25k
| Previous Close | 93.13 |
| Open | 93.31 |
| Day Range | 92.94-93.92 |
| Bid | 93.17 x 800 |
| Ask | 93.25 x 1k |
| Volume | 871.25k |
| Average Volume | 12.48M |
| Market Cap | 235.57B |
| Beta | 0.36 |
| 52 Week Range | 70.89-95.72 |
| Trailing P/E | 17.00 |
| Foward P/E | 12.61 |
| Dividend (Yield %) | 2.96% |
| Ex-Dividend Date | 2022-06-14 |
Financial Details
Organization
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuti... cals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Market Cap:
235.57BRevenue:
48.7BTotal Assets:
105.69BTotal Cash:
8.1B
News about "Merck & Co., Inc."
Merck - Seagen deal makes senses even at $250 per share price – Wells Fargo
Source from : Seeking Alpha - 7 hours ago
Wells Fargo argued on Thursday a buyout offer for Seagen (SGEN) could still make sense at $250 per share after The Wall Street Journal reported that Merck (MRK) was in advanced ...See details»
Merck Reportedly In Advanced Talks To Buy Seagen
Source from : Nasdaq - 16 hours ago
The companies are discussing a price for Seagen above $200 per share, the report specified. Merck and Seagen are seeking to seal a deal on or before the announcement of Merck's second fiscal-quarter ...See details»
Merck in talks to buy cancer biotech Seagen: report
Source from : Fox Business - 16 hours ago
Merck & Co is reportedly in talks to acquire biotech company Seagen Inc. in a nearly $40 billon deal that would add to the company's cancer drug portfolio.See details»
Merck in advanced talks to buy Seagen in nearly $40-billion deal - WSJ
Source from : Reuters on MSN.com - 17 hours ago
Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly $40 billion or more, the Wall Street Journal reported on Wednesday.See details»
Merck & Co. Inc. (MRK): How investors can get the most out of their investments
Source from : investchronicle - 2 days ago
For the readers interested in the stock health of Merck & Co. Inc. (MRK). It is currently valued at $91.22. When the transactions were called off in the previous session, Stock hit the highs of $92.49 ...See details»
Merck in “advanced talks” for $40bn Seagen bid; report
Source from : pharmaphorum - 10 hours ago
Rumour that Merck is preparing a bid for Seagen is gathering strength, with latest reports suggesting it could value the cancer biotech at $40bn ...See details»
Merck eyes $40 bln deal for biotech Seagen - WSJ
Source from : Reuters - 9 hours ago
Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen in a deal that could be worth $40 billion or more, the Wall Street Journal reports.See details»
Seagen Shares Rise Premarket as Merck Reportedly Moves Closer to Deal >SGEN
Source from : MarketWatch - 10 hours ago
By Colin Kellaher Shares of Seagen Inc. rose 5% in premarket trading Thursday after The Wall Street Journal reported that Merck & Co. is closing in on ...See details»
Merck Is in Advanced Talks to Acquire Biotech Firm Seagen
Source from : Yahoo Finance - 7 hours ago
Merck & Co. is in advanced talks to acquire Seagen Inc. and could reach an agreement as soon as this month, people familiar with the matter said. Most Read from BloombergNatural Gas Soars 700%, ...See details»
Wedge Capital Management L L P NC Decreases Stock Holdings in Merck & Co., Inc. (NYSE:MRK)
Source from : Defense World - 11 days ago
Wedge Capital Management L L P NC decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 2.9% during the first quarter, according to the company in its most recent disclosure ...See details»
Merck & Co. Inc. (NYSE: MRK) Share Price Rose Recently, Although Trouble Is Still On The Horizon
Source from : stocksregister - 8 days ago
Merck & Co. Inc. (NYSE:MRK) traded at $92.56 at last check on Wednesday, June 29, made an upward move of 0.73% on its previous day’s price. Looking at the stock we see that its previous close was $91.See details»
This Acquisition Could Make Merck a Scorching-Hot Buy
Source from : The Motley Fool - 8 days ago
According to reports, Merck is looking at potentially acquiring Seagen. Seagen is a biotech focused on developing innovative treatments for cancer. The deal could help both companies become bigger and ...See details»
8 Analysts Have This to Say About Merck & Co
Source from : Business Insider - 10 days ago
These 8 analysts have an average price target of $96.25 versus the current price of Merck & Co at $95.01, implying upside. Below is a summary of how these 8 analysts rated Merck & ...See details»
A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
Source from : Seeking Alpha - 3 days ago
The most recent two hottest potatoes in the biotech arena are Aurinia and Seagen. See why we think AUPH should be on the long side and Merck in the short side.See details»